FSD1L抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09066(FSD1L Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09066(FSD1L Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The FSD1L (Fibronectin type III and SPRY domain-containing protein 1-like) antibody is a tool used to study the FSD1L protein, a less characterized member of the fibronectin type III domain-containing protein family. FSD1L is structurally defined by its fibronectin type III (FN3) and SPRY domains, suggesting potential roles in protein-protein interactions, cellular adhesion, or signaling pathways. Though its exact biological function remains unclear, FSD1L is hypothesized to participate in cellular processes such as tissue development, immune regulation, or intracellular signaling, based on domain homology with related proteins.

FSD1L antibodies are primarily employed in research to detect and localize the protein in various biological samples via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies aid in elucidating FSD1L expression patterns across tissues, its subcellular distribution, and potential alterations in disease contexts. Emerging studies explore its relevance in cancer, neurological disorders, or immune dysregulation, though conclusive evidence is limited.

Commercial FSD1L antibodies are typically developed in rabbit or mouse hosts, with validation focusing on specificity and cross-reactivity. Researchers utilize these reagents to probe FSD1L's interactions, post-translational modifications, or regulatory mechanisms. Further work is needed to clarify its physiological and pathological roles, positioning FSD1L antibodies as critical tools for unraveling its function in health and disease.